Member Info for JimiHendrix

I echo all the points made by Choochie in their very good post below. I’m currently undecided which way I’ll vote and hope to hear more from Mr Nugent regarding his intentions. I currently hold 20m shares.

Actually no EC, once a would-be acquirer has paid 2.9 p within the last 12 months, all ordinary shares – including those issued in the recent dilution – must be bought at more than 2.9p each. The share count may increase, but the per-share floor does not shrink

I understand a take over would be at the highest price the party has paid in the past 12 months. This could have been as high as 2.6p ish, ten bagger from where we are at the moment.

It’s very possible he’s been buying on the open market, there have been a regular stream of huge buys over the past week or so.

They’re expecting FY 26 revenue to ramp up following preliminary international sales. Also the large near-medium term markets seem to be from overseas customers. That does sound like they’re expecting some decent revenue soon from Europe/ME …possibly before widespread UK adoption.

So to summarise, If Mr Nugent took place in the retail offer, we won't know until after 16th October when the retail offer shares are admitted to trading.

To clarify the confusion...

The Firm Placing Shares were expected to be admitted around 26 September 2025.

The Retail Offer / Conditional Placing Shares are expected to be admitted on 16 October 2025 (or a later date up to 30 October, if agreed)

...

Because the retail shares aren’t admitted until 16 October, any increase in shareholding from participating in the retail offer wouldn’t show in the TR-1 tied to the 26 September admission.

If a major holder like David Nugent subscribes in the retail offer and their holding crosses a disclosure threshold (e.g. 3%, 5%, etc.) as a result, a new TR-1 would be required after 16 October, reflecting post-admission holdings.

He may have done but that won't be reflected or declared until after those shares are issued.

If CYP2C19 is commissioned from April when the POC funding mandate goes live then there is a very strong probability they’ll achieve EBITDA positive in calendar year 2026. Bare in mind FY27 begins July 1st 2026, so the company saying by H2 FY27 it could easily happen in H1 and at the very least we will see sales ramping up through the year as we approach H2 FY27.

They already have visibility of £800k income after just the first 3 months of the current financial year, with more expected. If that’s a guide to go on, they could be looking at over £3m by the end of the current financial year June 26. Hopefully a lot more when NHSE rollout the funding pathway for CYP2C19.

I've just checked those big trades reported after hours today, with the prices at the trade time yesterday, and they're sells unfortunately. Doesn't mean it's not the next GGP though, next week will be interesting.

I’m sure I had a notice on Monday to say interims were due today.

Mcap will increase when the new shares are issued.

GoldieLock is right imo. Even after the full 2 billion shares are in issue, a share price of 1p equates to a mcap of only £20m. This is nothing considering the revenue that's anticipated from the NHS near-medium term.

Might be some significance in the new funding being announced yesterday, which was also the cutoff for registration for EMQN’s CYP2C19 POCT EQA... the EMQN catalogue shows the new CYP2C19 POCT EQA and related device-verification sample packs with registration closing on 22–23 Sept 2025. That’s the kind of quality-assurance infrastructure trusts need before scaling POCT across networks.

The EQA going live with Sept registration cut-offs is a practical pre-requisite for broad POCT deployment. EQA cycles tend to precede or run alongside service roll-outs so sites can demonstrate competency; seeing CYP2C19 POCT EQA advance now is consistent with preparation for wider adoption, even if central funding/commissioning hasn’t been declared yet.

Microbix press release (23 Sept) flags it is assisting EMQN with this CYP2C19 POCT EQA, underscoring that the scheme is live and being operationalised now.

Wini, he could employ someone to better manage certain areas. Besides I believe he's had a lot of success with his businesses in the past.

Exactly my thoughts.

Most of the red trades this morning were buys, I did many dummy trades on both sides to get some understanding what is happening.

There’s a pretty good chance the NHS will commission CYP2C19 testing by then, the company still awaits the implementation guide before they can comment on the potential revenue it’ll bring.

I think the share price will recover significantly from here, it’s just a real shame the discount was so painfully low.

If there was positive NHS news coming I doubt they would have added a year on to their EBITDA positive statement. That is what has done it for me, they’ve not even taken accountability for it, no explanation whatsoever. Until they explain what has changed, they’ve lost my trust.